AVCTF
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.05 | $56,990 | -$11M |
| 2025 Q2 | -0.04 | $56,000 | -$19M |
| 2024 Q2 | -0.04 | $11M | -$13M |
| 2023 Q4 | -0.05 | $11M | -$8M |
| 2023 Q2 | -0.04 | $12M | -$9M |
| 2022 Q4 | -0.12 | $4M | -$11M |
| 2022 Q2 | -0.04 | $6M | -$6M |
| 2021 Q4 | -0.06 | $620,000 | — |